Compliance Risk Management of Investigator Initiated Trials on Children Rare Diseases: Medical Institution Perspective
There is a substantial unmet need for treatments in the field of pediatric rare diseases, and investigator initiated trial(IIT) provide a critical pathway for testing and developing new drugs or treatment strategies. However, healthcare institutions, when conducting such research, must address compl...
Saved in:
| Main Authors: | ZHANG Jingqi, ZUO Liandong, GAO Xueqi, SI Wenyue, LUO Rui, WU Qiang, ZHOU Wenhao |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Rare Diseases
2025-01-01
|
| Series: | 罕见病研究 |
| Subjects: | |
| Online Access: | https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2025.01.017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigator Initiated Trials: modern trends
by: A. G. Torubarova, et al.
Published: (2019-01-01) -
Experience and lessons learned relating to investigational product supply in the design and delivery of a paediatric investigator-initiated clinical trial
by: Mandy Wan, et al.
Published: (2025-08-01) -
Investigation of Procedural Decisions at the Beginning of Pre-Trial Investigation
by: Yа. A. Burlaka
Published: (2020-12-01) -
Enhancing pragmatic competence in investigator-initiated clinical trials: structure and evaluation of the CONSCIOUS II training programme
by: Jitka Rychlíčková, et al.
Published: (2025-04-01) -
LiverRCTIIT: Promoting Investigator‐Initiated Randomized Controlled Trials for the Key Clinical Issues in Liver Disease Prevention and Treatment
by: Xiaolong Qi, et al.
Published: (2025-03-01)